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Abstract With advancing therapeutic options, achieving a
state of remission has become the treatment goal in
rheumatoid arthritis. Agreeing on what constitutes remis-
sion and what measures should be used to assess disease
activity has remained a challenge. Multiple remission
criteria have been devised and modified, all with different
strengths and limitations. A consensus definition of
remission will need to be achieved if we are to be able to
evaluate outcomes of clinical trials and establish treatment
targets for practice. Remission defined as the complete
absence of disease currently may not be a realistic
therapeutic goal.
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Introduction
As new disease-modifying agents and biologic therapies are
added to the treatment options in rheumatoid arthritis (RA),
better outcomes are expected and reported. The current
treatment goal for RA is to achieve a state of disease
remission. The concept of remission at first glance seems
simple. It has been defined as “an absence of articular and
extra-articular inflammation and disease activity” [1].
However, no consensus exists on what constitutes clinical
remission and what indices should be used to assess disease
activity. Presently, no gold standard can be uniformly
applied in clinical trials or practice.
In clinical practice, a subjective definition of remission is
commonly applied, one in which “we can recognize it when
we see it.” Three clinical domains are usually considered in
making this decision: signs and symptoms of inflammation,
functional impairment, and structural joint damage [2]. In a
2008 study evaluating physician and patient perspectives on
remission, rheumatologists were asked, “Based on your
experience, is your patient currently in remission?” while
patients completed questionnaires regarding their disease
activity. There was a 78.6% agreement (κ, 0.53) between
patients and physicians regarding achievement of remis-
sion. However, most of these RA patients were found to
have evidence of residual RA activity based on RA Disease
Activity Index scores, which called into question whether
subjective clinical remission is true absence of disease or a
state of low disease activity [3].
One of the first descriptions of remission in RA came
from Short and Bauer [4] in 1948, in which patients were
classified as being in remission if they were asymptomatic
and if examination of the joints was negative except for
residual deformity. Since that time, various criteria have
been developed to define remission using different clinical,
laboratory, and radiographic measures. Clinical trials have
used different definitions of remission, making it difficult to
compare results between studies. To standardize the
remission measure, the American College of Rheumatology
(ACR) and the European League Against Rheumatism
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RA and tocreate a uniform definition thatcan be usedin trials
and clinical practice. They believe that a strict definition of
remission is neededand shouldbevalidatedagainst long-term
outcomes [5￿￿]. This review discusses current debates in
remission, existing definitions, and their limitations.
Current Remission Criteria
Groups such as the ACR, EULAR, and the US Food and
Drug Administration (FDA) have all developed different
criteria to define remission (Tables 1 and 2).
ACR Criteria
One of the early attempts to define remission in RA was
adopted by the American Rheumatism Association (now
ACR) in 1981. Remission required fulfillment of 5 of 6
variables for at least 2 consecutive months: less than 15 min
of morning stiffness, no fatigue, no joint pain by history, no
joint tenderness, no swelling, and an erythrocyte sedimen-
tation rate (ESR) of less than 30 mm/h for women and less
than 20 mm/h for men [1]. Three of these six variables rely
on the patient’s history. It also should be noted that these
criteria were established at a time when available treatment
options did not provide the degree of improvement that is
currently expected and possible [6].
Prevoo et al. [7] proposed modifying the ACR criteria
because no specifications were provided on how to measure
the variables, and because fatigue and morning stiffness are
not currently recognized and accepted in a validated core
set. Fatigue was removed, and having no joint pain by
history was replaced by pain assessment on a Visual
Analogue Scale (VAS). Remission required meeting four
of the five variables of the revised criteria for 3 months [7].
One criticism regarding the ACR remission criteria is that
additional factors that may contribute to joint pain (eg,
structurally damaged joints) may not necessarily reflect
ongoing disease activity. Moreover, it would be possible to
fulfill remission criteria while still having swollen joints
[6]. In addition, clinical trials do not routinely gather all
data required to evaluate ACR remission criteria, and
several studies have modified assessments of ACR remis-
sion criteria, excluding fatigue, stiffness, or modifying pain
VAS measures [8]. Despite these limitations, the ACR
remission criteria are still viewed as reliable outcome
measures.
The ACR remission criteria should not be confused with
the ACR response criteria. Remission is a “status” measure
(ie, an assessment of disease activity at a specific point in
time), whereas a “response” measure is an assessment of
how disease activity changes over time. The ACR 20%,
50%, and 70% improvement criteria are response measures
and were developed to evaluate a response to therapy in the
context of a clinical trial, not to determine remission [9].
EULAR Criteria: Disease Activity Score
The Disease Activity Score (DAS) was proposed by EULAR
in the early-1990 s. The DAS is a single-point, absolute
measureofdiseaseactivity.TheoriginalDAS—theDAS44—
uses four core set variables in a mathematical equation to
quantifythe level ofdisease activity. The variables include the
Ritchie Tender Joint Index (a graded measurement of joint
tenderness), the number of swollen joints (44 joints assessed),
an acute-phase reactant (ESR or C-reactive protein [CRP]),
and a general health score on a 100-mm VAS. A DAS44/ESR
four-item score of less than 1.6 is considered remission. An
abbreviated version, the DAS28, has been validated against
the original version. A DAS28 score of less than 2.6 is
considered remission [10].
The DAS28 is more time efficient, requiring the evaluation
of fewer joints. However, the 28-joint count could lead to an
underestimation of disease activity. Ankles and feet are
commonly affected in RA but are not included in the
Table 1 ARA and modified ACR criteria for remission in rheumatoid arthritis
ARA criteria
a Modified ACR criteria
b
1. Morning stiffness<15 min 1. Morning stiffness<15 min
2. No joint pain by history 2. Pain on Visual Analogue Scale e10 mm (100 mm scale)
3. No joint tenderness on examination 3. No joint tenderness on examination
4. No joint or tendon sheath swelling 4. No joint or tendon sheath swelling
5. ESR<30 mm/h (women) or<20 mm/h (men) 5. ESR<30 mm/h (women) or <20 mm/h (men)
6. No fatigue
aMinimum 5 of 6 over 2 mo
bMinimum 4 of 5 over 3 mo
ACR American College of Rheumatology, ARA American Rheumatism Association, ESR erythrocyte sedimentation rate
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have been detected in many patients classified as being in
DAS28 remission [11￿]. In a study comparing the DAS28
with a DAS32 that included ankles and a combined
metatarsophalangeal joint count, the frequency of remission
did not change between the two definitions (n=767, 95%
concordance). For those with ankle and foot involvement,
abnormal acute-phase reactants or general health scores
increased DAS28 scores to levels above remission [12].
However, a substantial number of RA patients can have
tender and swollen joints and still be considered in DAS
remission [13]. Thus, it can be argued that DAS remission
reflects a measure of minimal RA disease activity rather than
remission.
Another limitation of the DAS is that it relies heavily on
acute-phase reactants. A subnormal ESR or CRP may
artificially weigh the DAS score into remission despite
objective evidence of disease activity in the joint count.
Subnormal inflammatory markers may be possible given
current biologictherapies thathavebeenshowntodrive down
acute-phase reactants without necessarily having equivalent
clinical improvement. On the flip side, ESR and CRP are
nonspecific and may not accurately reflect the patient’s
disease activity if they are elevated for other reasons (eg,
age, comorbidities). When the DAS28 is used instead of the
DAS44, the acute-phase reactant becomes more heavily
weighted, further amplifying changes in this variable [10].
Derivatives of EULAR Criteria: Disease Activity Indices
The Simplified Disease Activity Index (SDAI) and the
Clinical Disease Activity Index (CDAI) are less complex
composite indices that have been derived from the DAS.
The SDAI includes five components that are simply added
together for a final score: 28 tender joint count, a 28
swollen joint count, CRP, and both a patient’s and a
physician’s global disease activity based on a 10-cm VAS.
The CDAI is exactly the same except that it excludes the
CRP component and is therefore one of the few criteria that
does not involve a laboratory value. Remission is defined as
an SDAI score of less than 3.3 or a CDAI score of less than
or equal to 2.8 [14].
An advantage of the SDAI and CDAI over the DAS is
that they do not require a complex formula or a calculator
and can be used more readily in clinical practice. As they
are derived from the DAS, though, the disease activity
indices carry similar limitations. Interestingly, RA patients
who met SDAI remission criteria had less joint inflamma-
tion by power Doppler ultrasonography than patients who
met DAS28 remission criteria [15]. Patients with RA in
CDAI remission also have been shown to have quality-of-
life scores closer to those of the healthy population when
compared with patients who meet DAS28 remission criteria
[16]. These studies suggest that SDAI and CDAI remission
scores are stringent and may more accurately reflect a state
of decreased disease activity than DAS28 remission scores.
When SDAI and CDAI were compared with the DAS28
in a clinical practice setting, significantly fewer RA patients
met CDAI/SDAI remission than DAS28 remission [17].
This highlights the point that there are different remission
rates depending on the definition used. In a large,
multinational, cross-sectional cohort of 5848 RA patients
in 24 countries, 8.6% met ACR criteria for remission,
13.8% met CDAI remission criteria, and 19.6% achieved
DAS28 remission—numbers that are consistent with the
ACR criteria being the most difficult to fulfill and the
DAS28 being more inclusive [18￿￿]. Therefore, clinical
trials must be interpreted carefully in light of the remission
definitions being used.
FDA Criteria
The FDA criteria define remission as meeting the above
ACR remission criteria plus radiographic arrest (defined by
Larsen or Sharp scores) for 6 months after all antirheumatic
therapy has been discontinued. This is the only definition
that includes radiographic changes as well as a medication-
free state. These is the most stringent of all the criteria, and
no therapy to date has been able to fulfill the requirements
(Fig. 1)[ 19].
Table 2 Remission criteria for rheumatoid arthritis
Criteria Formula used to calculate score Required score
DAS44 DAS44 ¼ 0:56»sqrt RAI ðÞ þ 0:065» swollen44 ðÞ þ 0:33»ln ESR ðÞ þ 0:0072»GH < 1.6
DAS28 DAS28 ¼ 0:56»sqrt tender28 ðÞ þ 0:28»sqrt swollen28 ðÞ þ 0:70»ln ESR ðÞ þ 0:014»GH < 2.6
SDAI SDAI ¼ swollen28 þ tender28 þ CRP mg=dL ðÞ þ patient10   cmVAS þ physician10   cmVAS < 3.3
CDAI CDAI ¼ swollen28 þ tender28 þ patient10   cmVAS þ physician10   cmVAS < 2.8
FDA ACRcriteria þ radiographicarrest byLarsenorSharpmethod ðÞ for6moaftermedicationsdiscontinued –
ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS Disease Activity Score, ESR
erythrocyte sedimentation rate, FDA US Food and Drug Administration, GH General Health score, ln logarithm, RAI Ritchie Articular Index,
SDAI Simplified Disease Activity Index, sqrt square root, VAS Visual Analogue Scale
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The concept that remission in RA should require a disease-
free state after the discontinuation of medications is
debatable. At present, the cause for the immune dysregu-
lation that leads to RA is unknown. Current treatment aims
to control the disease, not cure it. Thus, is it theoretically
possible to achieve remission while being off treatment if
the underlying immune pathology is still present? [20]. It is
also known, however, that a wide spectrum of possible
disease outcomes exists for patients with RA, ranging from
mild to rapidly destructive and debilitating disease. Drug-
free remission has been previously reported in a small
proportion of RA patients. Within this subset of patients, it
is unclear whether current therapies are inducing a greater
rate of drug-free remission or if the observed percentages
represent the natural history of RA subtypes. The few
studies addressing drug-free remission vary in how remis-
sion is defined, making them difficult to compare [21].
Tippana-Kinnunen et al. [22￿￿] observed 87 patients with
early RA for 15 years treated by the “sawtooth strategy.”
Disease-modifying antirheumatic drugs (DMARDs) were
discontinued in 29% of patients who met the modified ACR
criteria of remission (excluding fatigue) or who had an
undefined symptom-free period. However, 11 of the
patients off medications (45%) had disease flares and had
to be restarted on DMARDs. The mean DMARD-free
period was 50 months overall (range, 3–137). None of the
patients who had to restart DMARD therapy were in
remission at the end of 15 years, suggesting that it may
be more difficult to control RA after medications have been
stopped and then restarted. The authors concluded that most
patients with long-standing RA require continuous
DMARD treatment, and if the treatment is discontinued,
patients should be followed up closely to monitor for flares
[22￿￿].
A 4-year follow-up to the BeSt (Dutch acronym for
Behandel–Strategieen treatment strategies) study looked at
drug-free remission in 508 patients with recent-onset, active
RA. Four different treatment strategies were adjusted every
3 months to achieve a DAS of less than 2.4. From year 2
onward, if the patient had a DAS less than 1.6 for at least 6
consecutive months, all antirheumatic treatment was dis-
continued. Between months 24 and 48, drug-free remission
was achieved in 20% (n=102). By the end of 4 years, 13%
(n=67) were still in drug-free remission, with the other
patients requiring reinitiation of treatment. The mean
duration of drug-free remission was 9 to 11 months.
Treatment strategy was not associated with drug-free
remission. Patients with milder RA at baseline, the absence
of autoantibodies, male gender, and shorter symptom
duration were associated with drug-free remission at year 4
[23].
Another study of the Leiden Early Arthritis Clinic (EAC)
and the British Early Rheumatoid Arthritis Study (ERAS)
also looked at the prevalence and predictive factors related
to DMARD-free remission. Remission was defined as
having no swollen joints, being off DMARDs, and
classified as being in remission by a rheumatologist for a
total duration of 1 year. Sustained DMARD-free remission
was achieved in 15% of the EAC group (68 of 454 patients)
and 9.4% of the ERAS group (84 of 895 patients). Factors
associated with remission included acute onset, short
symptom duration, nonsmokers, little radiographic damage
at baseline, absence of rheumatoid factor, and absence of
HLA shared epitope alleles [24￿].
These studies suggest that a small proportion of early-
RA patients (9%–15%) will be able to achieve medication-
free remission for a sustained period of time and that certain
factors may help predict in which RA patients this would be
possible. However, up to 45% will require a reinitiation of
therapy, and RA treatment may be more difficult when
medications are restarted. These studies varied in how
remission was defined, making it difficult to determine how
to apply medication-free remission to clinical practice.
There are no clear guidelines as to if and when medications
should be stopped in RA.
Imaging in Remission
The purpose of having remission as a goal in RA treatment
is to prevent joint damage and disability. Active inflamma-
tion in RA is generally correlated with progressive joint
destruction. However, it has been shown that patients in
clinical remission by ACR criteria [25] and by DAS28
criteria [26] can develop erosions and joint damage on
radiographs of hands and feet when observed 2 to 5 years
later. The progression of joint damage despite clinical
remission suggests that traditional assessments of disease
activity may not be sensitive enough, thereby leaving levels
Fig. 1 Stringency of remission criteria for rheumatoid arthritis. US
Food and Drug Administration (FDA) criteria are the most difficult to
fulfill, whereas Disease Activity Score (DAS)28 criteria are the most
inclusive. ACR—American College of Rheumatology; CDAI—
Clinical Disease Activity Index; SDAI—Simplified Disease Activity
Index
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that radiographs, ultrasound, or MRI should be included in
remission criteria to better assess disease activity. At present,
the FDA definition of remission is the only criterion that
requires the absence of radiographic progression.
In a study using data from the PREMIER (A Multicen-
ter, Randomized, Double-Blind Clinical Trial of Combina-
tion Therapy With Adalimumab Plus Methotrexate Versus
Methotrexate Alone or Adalimumab Alone in Patients With
Early, Aggressive Rheumatoid Arthritis Who Had Not Had
Previous Methotrexate Treatment) trial, 794 patients with
early RA on three different treatment strategies were
monitored for radiographic progression. Remission as
defined by CDAI, SDAI, or DAS28 was achieved in 15%
of patients (n=119) by the second year of the trial.
Radiographic progression was significantly different be-
tween patients with 3, 6, or 9 additional months of
remission (P<0.05) regardless of the type of treatment
received. The shorter the duration of remission, the more
likely radiographic progression was found. Itwas concluded
that this was likely a carryover effect of past periods of
inflammation and that this latency should be considered when
evaluating radiographic outcomes in clinical trials and
remission [28].
MRI and ultrasound are now being used more
commonly to assess RA disease activity. Patients who
have met the modified ACR criteria and DAS28 criteria
for remission have ongoing synovitis by ultrasound [29].
Brown et al. [27] studied ultrasound and MRI images of
the hands of 107 RA patients who were considered to be
in remission by their rheumatologist, the DAS28, or the
modified ACR criteria. Regardless of which definition of
remission was used, MRI showed that 96% of patients had
synovitis and 46% had bone marrow edema, while
ultrasound showed that 73% had synovial hypertrophy
and 43% had increased power Doppler signal. No
significant difference was noted in the number of patients
with inflammation between those who met DAS28 or
ACR remission criteria. These findings suggest that
DAS28 and ACR criteria may not measure RA remission,
in that “true remission” should show the absence of
synovitis on imaging studies [27].
In a follow-up longitudinal study, 102 of the RA patients
thought to be in remission underwent routine radiographs,
ultrasound, and MRI at 12 months. Despite apparent
clinical remission, 19% of patients (n=17 [of 90 analyzed])
had continued deterioration in radiographic joint damage,
although 11 satisfied ACR and DAS28 remission criteria.
Inflammatory scores on ultrasound, especially power
Doppler signals, and MRI synovitis scores at baseline were
significantly associated with development of radiographic
damage over 1 year. This study documents the association
of subclinical inflammation with progressive structural
damage in RA patients in clinical remission. It also
supports the use of sensitive imaging techniques to more
accurately evaluate disease status and define the remission
state [30￿￿].
Subclinical inflammation detected by ultrasound and
MRI may predict which patients considered to be in
remission are likely to experience disease progression. In
another study of RA patients in remission by DAS less than
1.6, having a positive power Doppler signal on ultrasound
was the main predictor of relapse within 6 months [31￿].
Imaging could be valuable in therapeutic decisions, helping
clinicians decide whether patients in clinical remission
should continue, stop, or restart antirheumatic medications.
Currently, no guidelines exist on how to incorporate
imaging in clinical practice and trials.
Spontaneous Remission
Spontaneous remission is not uncommon in patients who
present with very early arthritis, some of whom may meet
criteria for RA over less than a few months. Spontaneous
remission is thought of as a “natural remission,” in which
disease activity essentially disappears, and medications are
no longer required. Spontaneous remission may be seen in
13% to 55% of individuals presenting with undifferentiated
arthritis, probably as a result of different underlying etiolo-
gies, such as a transient viral infection [32]. About one third
of patients with undifferentiated arthritis go on to develop
RA. In a study of three cohorts of recent-onset undifferen-
tiated arthritis from the United Kingdom, Germany, and the
Netherlands, the severity of morning stiffness and presence
of autoantibodies were the strongest predictors of progres-
sion to RA [33]. Spontaneous remission can be seen not only
in early undifferentiated arthritis but in RA pregnancy and
juvenile idiopathic arthritis (JIA) as well.
Pregnancy
Pregnancy has a beneficial effect on the signs and symptoms
of RA to the point at which patients can appear to have
spontaneous remission of disease activity. Prospective studies
have shown improvement in joint involvement in RA in two
thirds to three quarters of pregnancies [34]. Improvement
occurs for 50% to 76% of patients by the end of the first
trimester and is usually sustained throughout pregnancy.
However, within 3 months of delivery, relapse is observed in
90% of patients [35]. Most pregnant women with RA have
an uneventful course with no significant complications.
Except for slight intrauterine growth restriction in patients
with active disease (3.36 vs 3.52 kg birth weight in matched
controls; P=0.01), the outcome of pregnancy is favorable in
patients with RA [36].
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were observed during each trimester and postpartum. DAS28
scores decreased significantly (P=0.035) during pregnancy
and increased postpartum. In patients with DAS greater than
3.2 (n=52), about 48% had moderate improvement based on
EULAR-defined response criteria. In patients with DAS
greater than 2.6 and less than 3.2 (n=32), disease activity
was stable during pregnancy. Before conception, 10% of
patients were in DAS28 remission (DAS28<2.6). The
number of patients in remission increased during the first
trimester to 17%, and 27% achieved DAS28 remission by
the third trimester. However, only 18% were in remission by
the 12th week postpartum. Thirty-nine percent of patients
had a moderate flare postpartum. Less medication was used
during pregnancy compared with before conception and
postpartum. The authors showed that RA disease activity can
improve during pregnancy but that not as many patients
achieved disease remission as previously thought [37￿￿].
Juvenile Inflammatory Arthritis
Spontaneous remission also has been reported in JIA (a
heterogeneous group of childhood diseases that involve
chronic idiopathic inflammation of one or more joints). JIA
has three general subgroups: oligoarthritis, polyarthritis,
and systemic disease. Frequencies of remission range from
29% to 78% depending on the subtype of disease, the
definition of remission, and the study being reviewed [38].
The patterns of clinical remission within categories of JIA
were studied in 437 JIA patients for at least 4 years. Patients
were evaluated for episodes of inactive disease, clinical
remission on medication, and clinical remission off medica-
tion.A totalof89% ofpatients(n=391) experienced episodes
of inactive disease with a median length of 12.7 months.
Those with oligoarticular JIA (n= 2 5 8 )s p e n t6 0 %o ft h e i r
time in a state of inactive disease, whereas those with
polyarticular or systemic JIA spent on average 30% to 36%
of their time in a state of inactive disease. Twenty-six percent
of patients (n=228) had clinical remission off medication,
with 68% of this group having oligoarticular JIA. Thirty-six
percent of these episodes of remission off medication
persisted for 2 years, but only 6% persisted for 5 years. This
study shows that spontaneous remission in JIA is not as
common and sustainable as previously reported and more
likely to occur in the oligoarticular subtype [39].
Conclusions
RA is a complex inflammatory disorder with a wide spectrum
of manifestations and outcomes ranging from mild, limited
disease to severe, debilitating disease. We may be dealing with
distinct diseases leading to different probabilities of remission.
The exact etiology of RA is unknown, but further insights are
being made continuously. New disease-modifying and biologic
therapies are being introduced to suppress RA-associated
inflammation. With more effective treatment options, the goal
of treatment has become to achieve “remission.” Defining
remission, however, has remained a challenge. With varying
definitions of what constitutes remission, it is difficult to
compare results of current drug trials and to know how to apply
these results to clinical practice.
The current definitions of remission have major limitations.
A patient can have tender and swollen joints and still meet most
criteria for remission. Furthermore, it also has been shown that
subclinicalinflammationmaybepresentonimagingdespitethe
absence of clinical findings of disease activity, which could
explain continuing joint damage despite a remission state. This
continued progression of disease suggests that RA patients are
not achieving true remission. If remission is defined as the
complete absence of disease activity, these findings question
whether remission is currently an achievable target. A more
realistic treatment expectationi nc l i n i c a lp r a c t i c em a yb et o
achieve minimal disease activity rather than complete absence
of disease. Telling patients with RA that they are in remission
may lead to periods of undertreatment and give patients (and
physicians) a false sense of security, as patients are still at risk
of developing deformities. With improved therapeutic man-
agement and medication development, perhaps remission can
be a realistic goal in the future.
Many questions remain unanswered. Should remission
be defined as the complete absence of disease, including
signs, symptoms, inflammatory markers, and imaging?
S h o u l di ta p p l yt oam o m e n ti nt i m eo rr e q u i r ead e f i n e d
duration or permanent cure? Should remission permit
treatment or require a drug-free state? As previously
mentioned, a combined ACR and EULAR committee is
a t t e m p t i n gt or e d e f i n er e m i s s i o ni nR Aa n dt or e a c ha
consensus as to how to apply the definition to clinical
trials and practice. Many of these same questions were
proposed and discussed. The committee concluded that
the new definition should be strict, based on no or very
low disease activity, and that remission should be defined
independent of treatment, time course, and long-term
outcomes such as radiographic damage. Variables
deemed to be most important were tender joint count
(with more joints being included), swollen joint count,
and acute-phase reactants. A research agenda and
subsequent meetings were planned to further investigate
how to define remission [5￿￿].
At the present time, when planning or evaluating RA
therapeutic outcomes, it is important to carefully assess the
precise definition of what is considered to be remission. A
consensus definition of remission will help us evaluate
outcomes of clinical trials and to establish treatment targets
for practice.
360 Curr Rheumatol Rep (2010) 12:355–362Acknowledgments Dr. Ranganath is supported by ACR Research
and Education Foundation Career Development Bridge funding
awards and has received grant funding from the National Institutes
of Health.
Dr. Paulus is supported by an ACR Research and Education
Foundation Within Our Reach grant.
Disclosure Dr. Ranganath has received gifts/grants from UCB,
Roche, Amgen, and CycLex.
Dr. Paulus has served as a consultant for Amgen and has received
grant support from Amgen and Abbott Laboratories. No other
potential conflicts of interest relevant to this article were reported.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Papers of particular interest, published recently have been
highlighted as:
￿ Of importance,
￿￿ Of major importance
1. Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical
remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308–
1315.
2. Paulus HE: Defining remission in rheumatoid arthritis: what is it?
Does it matter? J Rheumatol 2004, 31:1–4.
3. Wolfe F, Boers M, Felson D, et al.: Remission in rheumatoid
arthritis: physician and patient perspectives. J Rheumatol 2009,
36:930–933.
4. Short CL, Bauer W: The course of rheumatoid arthritis in patients
receiving simple medical and orthopedic measures. N Engl J Med
1948, 238:142–148.
5. ￿￿ Van Tuyl LHD, Vlad SC, Felson DT, et al.: Defining remission
in rheumatoid arthritis: results of an initial American College of
Rheumatology/European League Against Rheumatism consensus
conference. Arthritis Rheum 2009, 61:704–710. This article
describes the ACR and EULAR collaboration to define remission
in rheumatoid arthritis. It outlines the current questions regarding
remission and the research agenda set out to reach a consensus
definition, concluding that a strict definition needs to be used.
6. Sesin CA, Bingham CO: Remission in rheumatoid arthritis:
wishful thinking or clinical reality? Semin Arthritis Rheum
2005, 35:185–196.
7. Prevoo ML, van Gestl AM, vant Hof MA, et al.: Remission in a
prospective study of patients with rheumatoid arthritis. American
Rheumatism Association preliminary remission criteria in relation
to the Disease Activity Score. Br J Rheumatol 1996, 35:1101–
1105.
8. Ma MHY, Scott IC, Kingsley GH, Scott DL: Remission in early
rheumatoid arthritis. J Rheumatol 2010 Jun 1 (Epub ahead of
print).
9. Ranganath VK, Khanna D, Paulus HE: ACR remission criteria
and response criteria. Clin Exp Rheumatol 2006, 24(Suppl 43):
S14–S21.
10. OmettoF,BotsiosC,RaffeinerB,etal.:Methodsusedtoassessremissionand
lowdiseaseactivityinrheumatoidarthritis.AutoimmunRev2009,9:161–
164.
11. ￿ Van der Leeden M, Steultjens MP, van Schaardenburg D, Dekker
J: Forefoot disease activity in rheumatoid arthritis patients in
remission: results of a cohort study. Arthritis Res Ther 2010, 12:
R3. This study highlights one of the limitations of the DAS28
criteria, showing that there can be significant forefoot disease
activity in patients who meet DAS28 remission criteria.
12. Kapral T, Dernoschnig F, Machold KP, et al.: Remission by
composite scores in rheumatoid arthritis: are ankles and feet
important? Arthritis Res Ther 2007, 9:R72.
13. Makinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an
appropriate tool to assess remission in rheumatoid arthritis? Ann
Rheum Dis 2005, 64:1410–1413.
14. Aletaha D, Smolen J: The Simplified Disease Activity Index
(SDAI) and the Clinical Disease Activity Index (CDAI): a review
of their usefulness and validity in rheumatoid arthritis. Clin Exp
Rheumatol 2005, 23(Suppl 39):100–108.
15. Balsa A, de Miguel E, Castillo C, et al.: Superiority of SDAI over
DAS-28 in assessment of remission in rheumatoid arthritis
patients using power Doppler ultrasonography as a gold standard.
Rheumatology 2010, 49:683–690.
16. Linde L, Sorensen J, Ostergaard M, et al.: Does clinical remission
lead to normalization of EQ-5D in patients with rheumatoid
arthritis and is selection of remission criteria important? J
Rheumatol 2010, 37:285–290.
17. Gulfe A, Aletaha D, Saxne T, Geborek P: Disease activity level,
remission and response in established rheumatoid arthritis:
performance of various criteria sets in an observational cohort,
treated with anti-TNF agents. BMC Musculoskelet Disord 2009,
10:41–49.
18. ￿￿ Sokka T, Hetland ML, Makinen H, et al.: Remission and
rheumatoid arthritis, data on patients receiving usual care in ?
twentyour<?thyc= countries. Arthritis Rheum 2008, 58:2642–
2651. This study compared the different definitions of remission
in a cohort of 5848 RA patients across 24 countries. It illustrates
that remission rates vary depending on the definition being used,
with the DAS28 being the most inclusive and the ACR criteria
the most strict.
19. Makinen H, Hannonen P, Sokka T: Definitions of remission for
rheumatoid arthritis and review of selected clinical cohorts and
randomized clinical trials for the rate of remission. Clin Exp
Rheumatol 2006, 24(Suppl 43):22–28.
20. Valesini G, Di Franco M, Spinelli FR, Scrivo R: Induction of
remission in rheumatoid arthritis. Rheumatol Int 2008, 29:131–
139.
21. Yvonne PM, Goekoop-Ruiterman YPM, Huizinga TW: Can we
achieve true drug-free remission in patients with RA? Nat Rev
Rheumatol 2010, 6:68–70.
22. ￿￿ Tippana-Kinnunen T, Paimela T, Kautanian H, et al.: Can
disease modifying anti-rheumatic drugs be discontinued in long-
standing rheumatoid arthritis? A 15 year follow-up. Scand J
Rheumatol 2010, 39:12–18. Of the drug-free remission papers,
the follow-up period of 15 years used here is the longest.
DMARDS were discontinued in RA patients meeting ACR criteria,
45% of whom had to be restarted on treatment due to disease
flares. None of the patients who had to restart DMARDs were in
remission by the end of 15 years.
23. Van der Kooij SM, Goekoop-Ruiterman YPM, de Vries-Bouwstra
JK, et al.: Drug-free remission, functioning and radiographic
damage after 4 years of response-driven treatment in patients with
recent-onset rheumatoid arthritis. Ann Rheum Dis 2009, 68:914–
921.
24. ￿ Van der Woude D, Young A, Jayakumar K, et al.: Prevalence of
and predictive factors for sustained disease-modifying antirheu-
matic drug-free remission in rheumatoid arthritis, results from two
large early arthritis cohorts. Arthritis Rheum 2009, 60:2262–2271.
This paper demonstrated that acute onset of symptoms, short
Curr Rheumatol Rep (2010) 12:355–362 361symptom duration, nonsmokers, little radiographic damage at
baseline, and absence of rheumatoid factor are associated with
higher rates of DMARD-free remission.
25. Molenaar ET, Voskuyl AE, Dinant HJ, et al.: Progression of
radiologic damage in patients with rheumatoid arthritis in clinical
remission. Arthritis Rheum 2004, 50:36–42.
26. Cohen G, Gossec L, Dougados M, et al.: Radiologic damage in
patients with rheumatoid arthritis in sustained remission. Ann
Rheum Dis 2007, 66:358–363.
27. Brown AK, Quinn MA, Karim Z, et al.: Presence of significant
synovitis in rheumatoid arthritis patients with disease-modifying
anti-rheumatic drug-induced clinical remission, evidence from an
imaging study may explain structural progression. Arthritis
Rheum 2006, 54:3761–3773.
28. Aletaha D, Funovits J, Breedveld FC, et al.: Rheumatoid arthritis
joint progression in sustained remission is determined by disease
activity levels preceding the period of radiographic assessment.
Arthritis Rheum 2009, 60:1242–1249.
29. Ozgocmen S, Ozdemir H, Kiris A, et al.: Clinical evaluation and
power Doppler sonography in rheumatoid arthritis: evidence for
ongoing synovial inflammation in clinical remission. South Med J
2008, 101:240–245.
30. ￿￿ Brown AK, Conaghan PG, Karim Z, et al.: An explanation of
the apparent dissociation between clinical remission and contin-
ued structural deterioration in rheumatoid arthritis. Arthritis
Rheum 2008, 58:2958–2967. This is an important paper showing
that RA patients in remission by ACR and DAS criteria can
continue to have subclinical inflammation by ultrasound and MRI.
Inflammatory scores on ultrasound, especially power Doppler
signals, and MRI synovitis scores at baseline were significantly
associated with development of radiographic damage over 1 year,
offering an explanation as to why RA patients in remission have
continued structural damage over time.
31. ￿ Scire CA, Montecucco C, Codullo V, et al.: Ultrasonographic
evaluation of joint involvement in early rheumatoid arthritis in
clinical remission: power Doppler signal predicts short-term
relapse. Rheumatology 2009, 48:1092–1097. This study illus-
trates that subclinical inflammation in patients who are thought
to be in remission may be a tool to help predict short-term
relapse of disease activity.
32. Pincus T, Kavanaugh A, Smolen AJ: Complexities in defining
remission in rheumatic disease. Clin Exp Rheumatol 2006, 24
(Suppl 43):S1–S6.
33. Van der Helm-van Mil AHM, Detert J, le Cessie S, et al.: Validation
of a prediction rule for disease outcome in patients with recent-onset
undifferentiated arthritis. Moving toward individualized treatment
decision-making. Arthritis Rheum 2008, 58:2241–2247.
34. Gromnica-Ihle E, Østensen M: Pregnancy in patients with
rheumatoid arthritis and inflammatory spondyloarthropathies. Z
Rheumatol 2006, 65:209–212, 214–216.
35. Nelson JL, Østensen M: Pregnancy and rheumatoid arthritis.
Rheum Dis Clin North Am 1997, 23:195–212.
36. Bowden AP, Barrett JH, Fallow W, Silman J: Women with
inflammatory polyarthritis have babies of lower birth weight. J
Rheumatol 2001, 28:355–359.
37. ￿￿ De Man YA, Dolhain RJ, van de Geijn FE, et al.: Disease
activity of rheumatoid arthritis during pregnancy: results from a
nationwide prospective study. Arthritis Rheum 2008, 59:1241–
1248. This paper looks at the disease activity of RA patients
during and after pregnancy. It demonstrates the increased rate of
remission as defined by DAS28 during pregnancy and the
increase flare rate postpartum. It also shows that RA remission
in pregnancy is not achieved as frequently as previously reported.
38. Lurati A, Salmaso A, Gerloni V, et al.: Accuracy of Wallace
criteria for clinical remission in juvenile idiopathic arthritis: a
cohort study of 761 consecutive cases. J Rheumatol 2009,
36:1532–1535.
39. Wallace CA, Huang B, Bandeira M, et al.: Patterns of clinical
remission in select categories of juvenile idiopathic arthritis.
Arthritis Rheum 2005, 52:3554–3562.
362 Curr Rheumatol Rep (2010) 12:355–362